These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2461537)

  • 1. Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments.
    Freed DM; Corkin S; Growdon JH; Nissen MJ
    Neuropsychologia; 1988; 26(6):895-902. PubMed ID: 2461537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin levels in CSF of Alzheimer patients: correlations with monoamine metabolites and neuropsychological test performance.
    Jolkkonen J; Helkala EL; Kutvonen R; Lehtinen M; Riekkinen PJ
    Psychoneuroendocrinology; 1989; 14(1-2):89-95. PubMed ID: 2471986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementia.
    Nybäck H; Nyman H; Schalling D
    Acta Psychiatr Scand; 1987 Dec; 76(6):648-56. PubMed ID: 2450445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
    Palmer AM; Sims NR; Bowen DM; Neary D; Palo J; Wikstrom J; Davison AN
    J Neurol Neurosurg Psychiatry; 1984 May; 47(5):481-4. PubMed ID: 6204017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ; Logue M; Growdon JH
    Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression.
    Molchan SE; Lawlor BA; Hill JL; Martinez RA; Davis CL; Mellow AM; Rubinow DR; Sunderland T
    Biol Psychiatry; 1991 Jun; 29(11):1110-8. PubMed ID: 1714776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia.
    Bråne G; Gottfries CG; Blennow K; Karlsson I; Lekman A; Parnetti L; Svennerholm L; Wallin A
    Alzheimer Dis Assoc Disord; 1989; 3(3):148-56. PubMed ID: 2477044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between cisternal CSF and plasma concentrations of HVA, MHPG, 5-HIAA, DA, and NA.
    Degrell I; Nagy E
    Biol Psychiatry; 1990 May; 27(10):1179-82. PubMed ID: 1692743
    [No Abstract]   [Full Text] [Related]  

  • 9. CSF monoamine metabolites in mania.
    Swann AC; Secunda S; Davis JM; Robins E; Hanin I; Koslow SH; Maas JW
    Am J Psychiatry; 1983 Apr; 140(4):396-400. PubMed ID: 6188381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.
    Corona GL; Cucchi ML; Frattini P; Santagostino G; Schinelli S; Romani A; Pola A; Zerbi F; Savoldi F
    Eur Arch Psychiatry Neurol Sci; 1989; 239(2):79-86. PubMed ID: 2478368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine metabolites in the CSF of epileptic patients.
    Laxer KD; Sourkes TL; Fang TY; Young SN; Gauthier SG; Missala K
    Neurology; 1979 Aug; 29(8):1157-61. PubMed ID: 37460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggression in humans correlates with cerebrospinal fluid amine metabolites.
    Brown GL; Goodwin FK; Ballenger JC; Goyer PF; Major LF
    Psychiatry Res; 1979 Oct; 1(2):131-9. PubMed ID: 95232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide.
    Roy A; Ninan P; Mazonson A; Pickar D; Van Kammen D; Linnoila M; Paul SM
    Psychol Med; 1985 May; 15(2):335-40. PubMed ID: 2410941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced concentrations of arginine vasopressin and MHPG in lumbar CSF of patients with Korsakoff's psychosis.
    Mair RG; Langlais PJ; Mazurek MF; Beal MF; Martin JB; McEntee WJ
    Life Sci; 1986 Jun; 38(25):2301-6. PubMed ID: 2425205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF monoamine metabolites in schizophrenic patients.
    Gattaz WF; Waldmeier P; Beckmann H
    Acta Psychiatr Scand; 1982 Nov; 66(5):350-60. PubMed ID: 6184954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF monoamine metabolites in old age dementias.
    Parnetti L; Gaiti A; Reboldi GP; Santucci C; Mecocci P; Brunetti M; Cadini D; Senin U
    Mol Chem Neuropathol; 1992; 16(1-2):143-57. PubMed ID: 1381590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease.
    Blennow K; Wallin A; Gottfries CG; Lekman A; Karlsson I; Skoog I; Svennerholm L
    Neurobiol Aging; 1992; 13(1):107-13. PubMed ID: 1371850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.
    Potter WZ; Scheinin M; Golden RN; Rudorfer MV; Cowdry RW; Calil HM; Ross RJ; Linnoila M
    Arch Gen Psychiatry; 1985 Dec; 42(12):1171-7. PubMed ID: 2416297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit.
    Mann JJ; Stanley M; Neophytides A; de Leon MJ; Ferris SH; Gershon S
    Neurobiol Aging; 1981; 2(1):57-60. PubMed ID: 7266742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of electroconvulsive therapy on CSF amine metabolites in schizophrenic patients.
    Cooper SJ; Leahey W; Green DF; King DJ
    Br J Psychiatry; 1988 Jan; 152():59-63. PubMed ID: 2458796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.